Child Growth Disorders — Causes, Short Stature, Diagnosis & Treatment Guide — Symptoms, Causes & Treatment | MyMedicPlus

Child growth disorders encompass a spectrum of conditions causing abnormal growth velocity — either failure to grow at expected rates (short stature, growth faltering) or, less commonly, excessively rapid growth (tall stature). Normal growth follows a predictable centile channel on standardised growth charts (WHO 0-2 years; UK-WHO 2-18 years) — deviation from this channel is more significant than absolute height. Short stature is defined as height below the 3rd centile (more than 2 SD below the mean) for age, sex, and ethnic group, or height below the child's genetically predicted mid-parental height by more than 8-9 cm. Growth disorders affect physical and psychosocial development. The most common causes are familial short stature and constitutional delay of growth and puberty (CDGP) — both normal variants accounting for 80% of referrals. Pathological causes requiring treatment include growth hormone deficiency (GHD), hypothyroidism, coeliac disease, inflammatory bowel disease, chronic kidney disease, Turner syndrome (45,X — affecting girls), and skeletal dysplasias.

Normal variants (most common): familial short stature (child's height tracks below 2nd centile but follows their genetically determined centile, consistent with parental heights); constitutional delay of growth and puberty (CDGP — delayed bone age, delayed puberty but ultimately normal adult height — 'late bloomer'; family history of delayed puberty). Endocrine causes: growth hormone deficiency (GHD — isolated or part of hypopituitarism; can be congenital or acquired from tumour/irradiation/trauma); hypothyroidism (acquired — Hashimoto's thyroiditis; congenital — detected by newborn screening); Cushing's syndrome (cortisol excess — iatrogenic from steroid use is most common); precocious puberty paradoxically causing short adult stature (rapid early growth accelerates bone maturation). Systemic conditions: coeliac disease (gluten-induced GI malabsorption — must be excluded in all unexplained short stature); inflammatory bowel disease; chronic kidney disease; cyanotic congenital heart disease; chronic severe asthma; malnutrition. Chromosomal/genetic: Turner syndrome (45,X — short stature, gonadal dysgenesis, webbed neck, cubitus valgus, in all girls with unexplained short stature); Noonan syndrome (normal karyotype, similar phenotype to Turner); Prader-Willi syndrome; SHOX gene haploinsufficiency (15-20% of cases previously labelled idiopathic short stature). Skeletal dysplasias: achondroplasia (FGFR3 mutation — rhizomelic short limbs, macrocephaly, trident hands).

Key assessment is growth velocity — height measured accurately every 6 months on calibrated Harpenden stadiometer. Falling through centile channels (crossing more than 2 centile lines) indicates poor growth velocity requiring urgent assessment. Symptoms suggesting underlying pathology (red flags): height significantly below mid-parental height target; growth velocity below 4 cm/year in a school-age child; height below 0.4th centile (more than 2.67 SD); disproportionate short stature (body disproportion — limbs shorter than trunk suggests skeletal dysplasia); dysmorphic features (Turner phenotype: webbed neck, shield chest, widely spaced nipples, lymphoedema; Noonan: ptosis, low-set ears, pulmonary stenosis); delayed puberty beyond age 13 in girls or 14 in boys; features of GHD: midline defects, small penis, hypoglycaemia in infancy, preceding brain tumour or irradiation; symptoms of hypothyroidism: poor concentration, constipation, dry skin, delayed puberty; GI symptoms suggesting coeliac disease or IBD. Tall stature: height above 97th centile with rapid growth velocity — consider constitutional tall stature, hyperthyroidism, excess GH (gigantism — rare), sex chromosome abnormalities (Klinefelter 47,XXY — tall stature, small testes, gynaecomastia).

Accurate height and weight measurement; plot on growth chart; calculate height velocity (SD score). Mid-parental height (MPH) calculation: boys: (father's height cm + mother's height cm + 13) / 2; girls: (father's height cm + mother's height cm − 13) / 2; target height range: MPH ± 8.5 cm. Bone age X-ray (left hand/wrist): bone age 2+ years behind chronological age suggests CDGP or GHD; bone age equal to chronological age with short stature suggests familial short stature or pathological cause. Blood tests: thyroid function (TSH, free T4); FBC; renal function; coeliac antibodies (tTG-IgA, with total IgA to exclude IgA deficiency); LFTs; inflammatory markers (ESR, CRP). In girls with unexplained short stature: karyotype (Turner syndrome). IGF-1 and IGFBP-3: low levels suggest GHD but not definitive. GH stimulation testing (provocation with insulin hypoglycaemia, glucagon, arginine, clonidine — peak GH below 20 mIU/L or below 7 ng/mL indicates GHD): definitive but requires specialist centre. MRI brain/pituitary: structural cause of GHD (craniopharyngioma, empty sella). Bone density (DXA) for chronic glucocorticoid use.

Treatment depends entirely on the underlying cause. Growth hormone deficiency: recombinant human growth hormone (rhGH) — daily subcutaneous injections (dose approximately 25-35 mcg/kg/day for GHD); dramatic height gain (additional 5-10 cm compared to untreated); licensed for GHD, Turner syndrome, Prader-Willi syndrome, chronic renal insufficiency, SGA (small for gestational age) born without catch-up growth, SHOX deficiency, and Noonan syndrome; treatment continues until growth plates fuse (bone age 15-16 years in boys, 14-15 in girls) or transition to adult GH therapy reviewed. Turner syndrome: rhGH from early childhood + low-dose oestrogen induction of puberty at approximately 12-13 years (increasing slowly over 2 years, followed by cyclic HRT for lifelong female sex hormone replacement). Hypothyroidism: levothyroxine replacement — normalises growth velocity within 3-6 months of adequate replacement. Coeliac disease: strict gluten-free diet leads to catch-up growth over 1-2 years. CDGP: reassurance and monitoring; short-course low-dose sex steroids (testosterone for boys, oestrogen for girls) can be used to induce puberty if severe psychological impact — does not affect final adult height. Achondroplasia: vosoritide (CNP analogue targeting FGFR3) approved for children aged 2 and above — increases annual height velocity. Surgical limb lengthening for some skeletal dysplasias.

Untreated growth hormone deficiency results in significantly reduced adult height (typically 4-6 cm below genetic potential) and adult GHD effects: reduced muscle mass, increased central obesity, reduced bone mineral density (osteoporosis risk), adverse cardiovascular risk profile, and impaired quality of life. Turner syndrome without GH therapy results in an average adult height of 143-147 cm, with additional cardiac risks (bicuspid aortic valve in 30%, coarctation in 10%), ovarian failure, and infertility. Untreated congenital hypothyroidism causes irreversible intellectual disability — treatment must start within 2 weeks of birth (detected by newborn bloodspot screening). Untreated chronic undernutrition (the most common global cause of growth failure) causes cognitive impairment, immune deficiency, and significantly increased childhood mortality in low- and middle-income countries.

Newborn bloodspot screening (heel prick) identifies congenital hypothyroidism and classic phenylketonuria — early treatment prevents growth failure and neurodevelopmental harm. Regular growth monitoring at health visitor checks (6-8 weeks, 1 year, 2.5 years in UK), and school nurse checks at age 4-5 and 10-11 (National Child Measurement Programme), allows early detection of growth faltering. Universal neonatal hearing screening and developmental assessment. For children on long-term corticosteroids (asthma, IBD, nephrotic syndrome): use lowest effective dose; monitor growth; consider bone density and supplementation. Optimise nutrition — chronic undernutrition is the most common cause of growth failure worldwide; ensure adequate protein, energy, and micronutrients (particularly zinc, iron, and vitamin D). Precocious puberty management prevents premature epiphyseal fusion and short adult stature — GnRH analogue therapy buys time for growth.

Seek urgent paediatric assessment (within days) for: a child with severe hypoglycaemia (seizures, loss of consciousness) — may indicate GHD or hypopituitarism; sudden unexpected severe growth faltering with systemic illness; signs of raised intracranial pressure (headache, vomiting, visual changes) — could indicate a craniopharyngioma or other pituitary tumour. Arrange non-urgent referral to paediatric endocrinology for: height crossing more than 2 centile lines downward over 6-12 months; height below the 0.4th centile with no family history; height significantly below mid-parental target; suspected Turner syndrome (short stature in any girl); failure to enter puberty by age 13 in girls or 14 in boys; features suggesting a systemic cause of growth failure despite normal routine blood tests. Contact your GP for: a child who appears shorter than peers without crossing centiles; growth concerns without objective growth chart documentation — always request formal measurements before assuming a problem exists.